Logo of the Physikalisch-Technische Bundesanstalt
symbolic picture: "magazines"

Determining biomarkers

PTB-News 2.2022
02.05.2022
Especially interesting for

biomedical research

bioanalytics

medical engineering

In biomedical research and clinical care, it is becoming ever more important to detect biomarkers (pathogenic proteins and cells) quantitatively in order to understand systemic processes or to make decisions as regards diagnostics and therapy.

 A patent application has been filed for accurate, platform-independent and calibration-free measurement procedures performed on xenon atoms. Developed by PTB, such procedures are an innovative technology for quantifying biomarkers that use xenon-binding antibodies as biosensors. This approach is an alternative to the radioactive or fluorophore markers used to date; it could also prove interesting for vaccine development. (Technology Offers 341 + 535)

Advantages

high detection sensitivity and accuracy

calibration-free measurement

platform-independent results

use of biosensors

Contact person for questions about technology transfer

Andreas Barthel, Phone: +49 531 592-8307, Opens local program for sending emailandreas.barthel(at)ptb.de, Opens internal link in current windowwww.technologietransfer.ptb.de/en

[ back ]